You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國家衛健委修訂新冠肺炎診療方案 輕型病例集中隔離管理
阿思達克 03-16 07:08
國家衛健委發佈《新型冠狀病毒肺炎診療方案(試行第九版)》。新版診療方案是在認真研究德爾塔、奧密克戎等變異毒株傳播特點和病例特徵,深入分析相關研究成果的基礎上形成的。 該方案根據各地反映的「奧密克戎變異毒株患者以無症狀感染者和輕型病例爲主,大多不需要過多治療,全部收治到定點醫院會佔用大量醫療資源」等意見,提到將進一步完善病例分類收治措施,包括:輕型病例實行集中隔離管理,相關集中隔離場所不能同時隔離入境人員、密切接觸者等人羣。隔離管理期間應做好對症治療和病情監測,如病情加重,應轉至定點醫院治療。 同時,普通型、重型、危重型病例和有重型高危因素的病例應在定點醫院集中治療,其中重型、危重型病例應當儘早收入ICU治療,有高危因素且有重症傾向的患者也宜收入ICU治療。 此外,方案提到,將進一步規範抗病毒治療,國家藥監局批準的兩種特異性抗新冠病毒藥物寫入診療方案,即PF-07321332/利託那韋片(Paxlovid)和國產單克隆抗體(安巴韋單抗/羅米司韋單抗注射液),以及結合各地臨牀救治經驗,加強中醫非藥物療法應用,增加鍼灸治療內容,並結合兒童患者特點,增加兒童中醫治療相關內容等。(ta/s) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account